NCT03930173: 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

NCT03930173
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Ph+ase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have received prior intracranial SRS at least once for brain metastases
Exclusions: 
https://ClinicalTrials.gov/show/NCT03930173

Comments are closed.

Up ↑